Effects of trimetazidine in the treatment of ischemic cardiomyopathy patients with chronic heart failure and diabetes mellitus
GAO Yi-na
LIU Hao
Abstract：Objective To observe the effects of trimetazidine in the treatment of ischemic cardiomyopathy ( ICM) patients with chronic heart failure( CHF) and diabetes mellitus.Methods Sixty ICM patients(42 males and 18 females) were collected from the Central Hospital of Zhumadian City from January 2013 to June 2014, and were diagnosed as New York Heart Association( NYHA) Class Ⅲ~Ⅳheart failure.All included patients were randomly divided into the control group and the treatment group.The treatment group was given the standard therapy including the angiotensin converting enzyme inhibitors(ACEI)/angiotensin receptor blockers(ARB), beta blockers, digitalis, diuretics and other medicines combined with trimetazidine 20 mg/TID( three times a day) to cure the heart failure for 6 months.The control group was given the same standard treatment combined with oryzanol for 6 months.Left ven-tricular end-diastolic diameter(LVEDD), left ventricular ejection fraction(LVEF), left ventricular end-systolic di-mension(LVESD), and 6-minute walking test(6MWT) were measured and compared between the two groups 6 months after the treatment.Results LVESD, LVEDD, LVEF and 6MWT in the treatment group improved better than those in the control group( P<0.05) .No adverse reactions were found in both of the two groups.Conclusion Trim-etazidine obviously improves the cardiac function of ICM patients with CHF and diabetes mellitus, and improves the quality of their lives.
Keywords：TrimetazidineDiabetes mellitusIschemic cardiomyopathy(ICM)Chronic heart failure ( CHF)
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 122-125 )